Klára Werling

Dr. Klára Werling

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2018 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
RBRob Bielen
Rob Bielen
SSSamya R. Stumo
Samya R. Stumo
RHRachel Halford
Rachel Halford
KWKlára Werling
Klára Werling
TRTatjana Reic
Tatjana Reic
JLJeffrey Lazarus
Jeffrey Lazarus
Current estimates suggest that 15% of all prisoners worldwide are chronically infected with the hepatitis C virus (HCV), and this number is even higher in regions with high rates of injecting drug use. Although harm reduction services such as opioid substitution therapy (OST) and needle and syringe programs (NSPs) are effective in preventing the further spread of HCV and HIV, the extent to which these are available in prisons varies significantly across countries. The Hep-CORE study surveyed liver patient groups from 25 European countries in 2016 and mid-2017 on national policies related to harm reduction, testing/screening, and treatment for HCV in prison settings. Results from the cross-sectional survey were compared to the data from available reports and the peer-reviewed literature to determine the overall degree to which European countries implement evidence-based HCV recommendations in prison settings. Patient groups in nine countries (36%) identified prisoners as a high-risk population target for HCV testing/screening. Twenty-one countries (84%) provide HCV treatment in prisons. However, the extent of coverage of these treatment programs varies widely. Two countries (8%) have NSPs officially available in prisons in all parts of the country. Eleven countries (44%) provide OST in prisons in all parts of the country without additional requirements. Despite the existence of evidence-based recommendations, infectious disease prevention measures such as harm reduction programs are inadequate in European prison settings. Harm reduction, HCV testing/screening, and treatment should be scaled up in prison settings in order to progress towards eliminating HCV as a public health threat.

19 August 2022 in Medicine
Verified
Journal Article
Open access
ARAladar Rónaszéki
Aladar Rónaszéki
BBBettina Budai
Bettina Budai
BCBarbara Csongrády
Barbara Csongrády
RSRóbert Stollmayer
Róbert Stollmayer
KHKrisztina Hagymási
Krisztina Hagymási
PKPal Novak Kaposi
Pal Novak Kaposi
We aimed to assess the feasibility of ultrasound-based tissue attenuation imaging (TAI) and tissue scatter distribution imaging (TSI) for quantification of liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD). We prospectively enrolled 101 participants with suspected NAFLD. The TAI and TSI measurements of the liver were performed with a Samsung RS85 Prestige ultrasound system. Based on the magnetic resonance imaging proton density fat fraction (MRI-PDFF), patients were divided into ≤5%, 5–10%, and ≥10% of MRI-PDFF groups. We determined the correlation between TAI, TSI, and MRI-PDFF and used multiple linear regression analysis to identify any association with clinical variables. The diagnostic performance of TAI, TSI was determined based on the area under the receiver operating characteristic curve (AUC). The intraclass correlation coefficient (ICC) was calculated to assess interobserver reliability. Both TAI (rs = 0.78, P < .001) and TSI (rs = 0.68, P < .001) showed significant correlation with MRI-PDFF. TAI overperformed TSI in the detection of both ≥5% MRI-PDFF (AUC = 0.89 vs 0.87) and ≥10% (AUC = 0.93 vs 0.86). MRI-PDFF proved to be an independent predictor of TAI (β = 1.03; P < .001), while both MRI-PDFF (β = 50.9; P < .001) and liver stiffness (β = −0.86; P < .001) were independent predictors of TSI. Interobserver analysis showed excellent reproducibility of TAI (ICC = 0.95) and moderate reproducibility of TSI (ICC = 0.73). TAI and TSI could be used successfully to diagnose and estimate the severity of hepatic steatosis in routine clinical practice.

26 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
Bálint DráczBálint Drácz
Bálint Drácz
DCDiána Czompa
Diána Czompa
KMKatalin Müllner
Katalin Müllner
KHKrisztina Hagymási
Krisztina Hagymási
MPMiheller Pal
Miheller Pal
KWKlára Werling
Klára Werling
Liver damage in COVID-19 patients was documented as increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels or an elevated AST/ALT ratio, known as the De Ritis ratio. However, the prognostic value of the elevated De Ritis ratio in COVID-19 patients is still unknown. The aim of our study was to evaluate the prognostic value of the De Ritis ratio compared to other abnormal laboratory parameters and its relation to mortality. We selected 322 COVID-19 patients in this retrospective study conducted between November 2020 and March 2021. The laboratory parameters were measured on admission and followed till patient discharge or death. Of the 322 COVID-19 patients, 57 (17.7%) had gastrointestinal symptoms on admission. The multivariate analysis showed that the De Ritis ratio was an independent risk factor for mortality, with an OR of 29.967 (95% CI 5.266–170.514). In ROC analysis, the AUC value of the the De Ritis ratio was 0.85 (95% CI 0.777–0.923, p < 0.05) with sensitivity and specificity of 80.6% and 75.2%, respectively. A De Ritis ratio ≥1.218 was significantly associated with patient mortality, disease severity, higher AST and IL-6 levels, and a lower ALT level. An elevated De Ritis ratio on admission is independently associated with mortality in COVID-19 patients, indicating liver injury and cytokine release syndrome.

31 October 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
PKPál Novák Kaposi
Pál Novák Kaposi
ZZZita Zsombor
Zita Zsombor
ARAladar Rónaszéki
Aladar Rónaszéki
BBBettina Budai
Bettina Budai
BCBarbara Csongrády
Barbara Csongrády
KHKrisztina Hagymási
Krisztina Hagymási
We aimed to develop a non-linear regression model that could predict the fat fraction of the liver (UEFF), similar to magnetic resonance imaging proton density fat fraction (MRI-PDFF), based on quantitative ultrasound (QUS) parameters. We measured and retrospectively collected the ultrasound attenuation coefficient (AC), backscatter-distribution coefficient (BSC-D), and liver stiffness (LS) using shear wave elastography (SWE) in 90 patients with clinically suspected non-alcoholic fatty liver disease (NAFLD), and 51 patients with clinically suspected metabolic-associated fatty liver disease (MAFLD). The MRI-PDFF was also measured in all patients within a month of the ultrasound scan. In the linear regression analysis, only AC and BSC-D showed a significant association with MRI-PDFF. Therefore, we developed prediction models using non-linear least squares analysis to estimate MRI-PDFF based on the AC and BSC-D parameters. We fitted the models on the NAFLD dataset and evaluated their performance in three-fold cross-validation repeated five times. We decided to use the model based on both parameters to calculate UEFF. The correlation between UEFF and MRI-PDFF was strong in NAFLD and very strong in MAFLD. According to a receiver operating characteristics (ROC) analysis, UEFF could differentiate between <5% vs. ≥5% and <10% vs. ≥10% MRI-PDFF steatosis with excellent, 0.97 and 0.91 area under the curve (AUC), accuracy in the NAFLD and with AUCs of 0.99 and 0.96 in the MAFLD groups. In conclusion, UEFF calculated from QUS parameters is an accurate method to quantify liver fat fraction and to diagnose ≥5% and ≥10% steatosis in both NAFLD and MAFLD. Therefore, UEFF can be an ideal non-invasive screening tool for patients with NAFLD and MAFLD risk factors.

3 June 2005 in Endoscopy
Verified
Journal Article
Open access
PDF file
EME Mihály
E Mihály
ANA Németh
A Németh
TZT Zágoni
T Zágoni
ANA Német
A Német
KWKlára Werling
Klára Werling
ZTZ Tulassay
Z Tulassay
The discovery of multiple gastrointestinal polyps during endoscopy indicates the presence of an inherited polyposis syndrome, but this finding can also be associated with noninherited polyposis syndromes, such as nodular lymphoid hyperplasia. Although nodular lymphoid hyperplasia can occur in the absence of immunodeficiency, it can be a manifestation of common variable immunodeficiency. Common variable immunodeficiency is a syndrome which is characterized by immature B lymphocytes that recognize antigens and proliferate in response to an antigen challenge, but which then fail to differentiate to become immunoglobulin-secreting plasma cells [ 1 ]. Possible factors suspected of causing this condition include an intrinsic abnormality of B lymphocytes, and dysfunction of T helper cells or of complement components. This abortive differentiation pattern leads to panhypogammaglobulinemia, recurrent sinopulmonary inflammation, splenomegaly, and intestinal lymphoid hyperplasia [ 2 ]. Because malignant tumors, such as lymphoma or stomach cancer, can develop in association with common variable immunodeficiency, annual surveillance of these patients is necessary [ 3 ]. We present a patient with gastrointestinal manifestations of common variable immunodeficiency. A 53-old-man, previously misdiagnosed as having Peutz-Jeghers syndrome, presented with chronic diarrhea, weight loss, and recurrent sinopulmonary infections. His laboratory results revealed panhypogammaglobulinemia. Gastroscopy demonstrated multiple polypoid structures, 3 - 5 mm in diameter, which covered the wall of the duodenum (Figure [ 1 ]). Histological examination of these structures revealed lymphoid hyperplasia with prominent germinal centers, giardiasis, and inflammation associated with Helicobacter pylori infection. Because nodular lymphoid hyperplasia predisposes to the development of lymphomas, capsule endoscopy was performed in order to exclude malignancy. Capsule endoscopy revealed the presence of the polypoid structures throughout the small intestine, and these were particularly numerous in the terminal ileum (Figure [ 2 ]). No signs of malignancy were seen. A diagnosis of lymphocytic colitis and nodular lymphoid hyperplasia was made in the sigmoid and transverse colon by colonoscopy, though other parts of the colon were unaffected by the syndrome. Figure 1 Endoscopic features of intestinal nodular hyperplasia. a The view of the duodenal lumen. b The polypoid surface of the duodenal wall. Figure 2 Capsule endoscopy revealed the presence of multiple polyps throughout the small intestine. These images were obtained from the proximal jejunum (a) and the terminal ileum (b). In this report we have presented an illustrative case of nodular lymphoid hyperplasia associated with common variable immunodeficiency. We have described the gastrointestinal manifestations of this uncommon disease in a patient with a noninherited polyposis syndrome, diagnosed by video- and capsule endoscopy.

2 February 2022 in Viruses
Verified
Journal Article
Open access
PDF file
KWKlára Werling
Klára Werling
BHBéla Hunyady
Béla Hunyady
MMMihály Makara
Mihály Makara
KNKrisztina Nemesi
Krisztina Nemesi
GHGábor Horváth
Gábor Horváth
ANAnna Nemes Nagy
Anna Nemes Nagy
A hepatitis C virus (HCV) screening and treatment program was conducted in Hungarian prisons on a voluntary basis. After HCV-RNA testing and genotyping for anti-HCV positives, treatments with direct-acting antiviral agents were commenced by hepatologists who visited the institutions monthly. Patients were supervised by the prisons’ medical staff. Data were retrospectively collected from the Hungarian Hepatitis Treatment Registry, from the Health Registry of Prisons, and from participating hepatologists. Eighty-four percent of Hungarian prisons participated, meaning a total of 5779 individuals (28% of the inmate population) underwent screening. HCV-RNA positivity was confirmed in 317/5779 cases (5.49%); 261/317 (82.3%) started treatment. Ninety-nine percent of them admitted previous intravenous drug use. So far, 220 patients received full treatment and 41 patients are still on treatment. Based on the available end of treatment (EOT) + 24 weeks timepoint data, per protocol sustained virologic response rate was 96.8%. In conclusion, the Hungarian prison screening and treatment program, with the active participation of hepatologists and the prisons’ medical staff, is a well-functioning model. Through the Hungarian experience, we emphasize that the “test-and-treat” principle is feasible and effective at micro-eliminating HCV in prisons, where infection rate, as well as history of intravenous drug usage, are high.